Literature DB >> 20627758

The interface between the innate interferon response and expression of host retroviral restriction factors.

Renée N Douville1, John Hiscott.   

Abstract

Inhibition of the expression and replication of human retroviruses by different families of host restriction factors has emerged as an important component of antiviral innate immunity. The term "intrinsic immunity" is used to define this specific arm of innate immunity and suggests that host restriction factors are constitutively present within infected cells. The essential role of the interferon (IFN) signaling pathways in eliciting host restriction factor gene transcription - triggered a consequence of pattern recognition receptor signaling - may be an under-recognized aspect of intrinsic immunity. This review discusses the relevance of innate IFN signaling in the induction of retroviral restriction factors, the mechanisms of action of these factors, as well as the counter-regulation of IFN response that results from the plethora of retrovirus-restriction factor interactions. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20627758     DOI: 10.1016/j.cyto.2010.04.010

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  15 in total

1.  Evolutionary and functional analyses of the interaction between the myeloid restriction factor SAMHD1 and the lentiviral Vpx protein.

Authors:  Nadine Laguette; Nadia Rahm; Bijan Sobhian; Christine Chable-Bessia; Jan Münch; Joke Snoeck; Daniel Sauter; William M Switzer; Walid Heneine; Frank Kirchhoff; Frédéric Delsuc; Amalio Telenti; Monsef Benkirane
Journal:  Cell Host Microbe       Date:  2012-02-01       Impact factor: 21.023

2.  Retroviral replicating vectors in cancer.

Authors:  Christopher R Logg; Joan M Robbins; Douglas J Jolly; Harry E Gruber; Noriyuki Kasahara
Journal:  Methods Enzymol       Date:  2012       Impact factor: 1.600

3.  In vivo hypermutation of xenotropic murine leukemia virus-related virus DNA in peripheral blood mononuclear cells of rhesus macaque by APOBEC3 proteins.

Authors:  Ao Zhang; Hal Bogerd; Francois Villinger; Jaydip Das Gupta; Beihua Dong; Eric A Klein; John Hackett; Gerald Schochetman; Bryan R Cullen; Robert H Silverman
Journal:  Virology       Date:  2011-10-06       Impact factor: 3.616

4.  RIG-I-mediated antiviral signaling is inhibited in HIV-1 infection by a protease-mediated sequestration of RIG-I.

Authors:  Mayra Solis; Peyman Nakhaei; Mohammad Jalalirad; Judith Lacoste; Renée Douville; Meztli Arguello; Tiejun Zhao; Michael Laughrea; Mark A Wainberg; John Hiscott
Journal:  J Virol       Date:  2010-11-17       Impact factor: 5.103

Review 5.  Human endogenous retroviruses and the nervous system.

Authors:  Renée N Douville; Avindra Nath
Journal:  Handb Clin Neurol       Date:  2014

Review 6.  Interplay between human cytomegalovirus and intrinsic/innate host responses: a complex bidirectional relationship.

Authors:  Giada Rossini; Cristina Cerboni; Angela Santoni; Maria Paola Landini; Santo Landolfo; Deborah Gatti; Giorgio Gribaudo; Stefania Varani
Journal:  Mediators Inflamm       Date:  2012-05-31       Impact factor: 4.711

Review 7.  HTLV-1 and innate immunity.

Authors:  Chloé Journo; Renaud Mahieux
Journal:  Viruses       Date:  2011-08-08       Impact factor: 5.048

Review 8.  Tetherin and its viral antagonists.

Authors:  Björn D Kuhl; Vicky Cheng; Mark A Wainberg; Chen Liang
Journal:  J Neuroimmune Pharmacol       Date:  2011-01-11       Impact factor: 4.147

9.  XMRV Discovery and Prostate Cancer-Related Research.

Authors:  David E Kang; Michael C Lee; Jaydip Das Gupta; Eric A Klein; Robert H Silverman
Journal:  Adv Virol       Date:  2011-06-21

10.  A whole genome screen for HIV restriction factors.

Authors:  Li Liu; Nidia M M Oliveira; Kelly M Cheney; Corinna Pade; Hanna Dreja; Ann-Marie H Bergin; Viola Borgdorff; David H Beach; Cleo L Bishop; Matthias T Dittmar; Aine McKnight
Journal:  Retrovirology       Date:  2011-11-14       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.